Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNB8802 in Healthy Volunteers and Enteric Hyperoxaluria
NCT04629170Phase 1Completed
- Sponsor
- Synlogic
- Start
- Nov 2020
- Primary completion
- Jan 2023
- Modality
- Gene Editing, Gene Silencing, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of synb8802 in enteric hyperoxaluria (EH) (8 arms), sponsored by Synlogic. Primary endpoint: Number of Subjects With Treatment-Emergent Adverse Events at 33 Days. Started Nov 2020; status: completed.
02
Drugs
synb8802
03
Conditions
enteric hyperoxaluria (EH)
Beyond the preview
Go deeper on NCT04629170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04629170.